Markus Möhler, Ines Gockel, Hans-Peter Roessler, Dirk Arnold, Tanja Trarbach, Thomas Thomaidis, Gunther Klautke, Claus Rödel, Baruch Brenner, Hauke Lang, Peter R. Galle, Carl Christoph Schimanski, Heinz Schmidberger
- Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction.
Methods: Patients received neoadjuvant radiotherapy (50.4 Gy) together with weekly docetaxel (20 mg/m2 at dose level (DL) 1 and 2, 25 mg/m2 at DL 3) and oxaliplatin (40 mg/m2 at DL 1, 50 mg/m2 at DL 2 and 3) over 5 weeks. The primary endpoint was the DLT and the MTD of the RCT regimen. Secondary endpoints included overall response rate (ORR) and progression-free survival (PFS).
Results: A total of 24 patients were included. Four patients were treated at DL 1, 13 patients at DL 2 and 7 patients at DL 3. The MTD of the RCT was considered DL 2 with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2. Objective response (CR/PR) was observed in 32% (7/22) of patients. Eighteen patients (75%) underwent surgery after RCT. The median PFS for all patients (n = 24) was 6.5 months. The median overall survival for all patients (n = 24) was 16.3 months. Patients treated at DL 2 had a median overall survival of 29.5 months.
Conclusion: Neoadjuvant RCT with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2 was effective and showed a good toxicity profile. Future studies should consider the addition of targeted therapies to current neoadjuvant therapy regimens to further improve the outcome of patients with advanced cancer of the oesophagogastric junction.
Trial Registration: NCT00374985
MetadatenVerfasserangaben: | Markus Möhler, Ines Gockel, Hans-Peter Roessler, Dirk Arnold, Tanja Trarbach, Thomas Thomaidis, Gunther Klautke, Claus RödelORCiDGND, Baruch Brenner, Hauke Lang, Peter R. Galle, Carl Christoph Schimanski, Heinz Schmidberger |
---|
URN: | urn:nbn:de:hebis:30:3-289372 |
---|
DOI: | https://doi.org/10.1186/1471-2407-13-75 |
---|
ISSN: | 1471-2407 |
---|
Titel des übergeordneten Werkes (Englisch): | BMC cancer |
---|
Verlag: | BioMed Central |
---|
Verlagsort: | London |
---|
Dokumentart: | Wissenschaftlicher Artikel |
---|
Sprache: | Englisch |
---|
Datum der Veröffentlichung (online): | 11.02.2013 |
---|
Datum der Erstveröffentlichung: | 11.02.2013 |
---|
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Datum der Freischaltung: | 22.02.2013 |
---|
Freies Schlagwort / Tag: | Chemoradiotherapy; Docetaxel; Neoadjuvant radiochemotherapy; Oesophagogastric cancer oxaliplatin |
---|
Jahrgang: | 13 |
---|
Ausgabe / Heft: | 75 |
---|
Seitenzahl: | 10 |
---|
Bemerkung: | © 2013 Moehler et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
---|
HeBIS-PPN: | 332436128 |
---|
Institute: | Medizin / Medizin |
---|
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Lizenz (Deutsch): | Creative Commons - Namensnennung 2.0 |
---|